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Introduction: Renal cell carcinoma is the most common form of malignant renal tumor. Clinical presentation of 
Sarcomatoid Renal Cell Carcinoma (sRCC) varies widely and is dependent on the stage at which the diagnosis has been 
reached. At the time of diagnosis, about one-third of patients develop metastasis affecting the lung, lymphatic, liver, bone, 
contralateral kidney, adrenal glands, and brain.  
Case Presentation: A 46 year old Hispanic female with no significant past medical history presents to the Emergency 
department with recurrent episodes of dizziness, difficulty breathing, dry mouth, weakness, and productive cough without 
blood. She initially presents with a rare initial dermatological finding related to her current condition.  
Conclusion: Sarcomatoid Renal Cell Carcinoma is a rare variant of RCC with stage-dependent outcomes. Initial 
presentations may not be very obvious in suspicion of sRCC. However, in this particular case, the external findings 
happened to be the initial presentation, prompting further evaluation of the patient. Delving into the features of sRCC and 
maintaining all possibilities may allow future workup of the more common variants of RCC to be included in the 
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Introduction 
Renal cell carcinoma is the most common form of malignant renal tumor, it accounts for 3% of all adult 
malignancies and it is extremely lethal. Variations of presentation of sarcomatoid Renal Cell Carcinoma 
(sRCC) depend on the stage of diagnosis. About one third of patients at the time of diagnosis develop 
metastasis affecting the lung, lymphatic ganglions, liver, bone, contralateral kidney, adrenal and 
ipsilateral glands, and brain skin metastases. However metastasis from RCC to the skin is much less 
common. [1, 2]. Sarcomatoid renal cell carcinoma is a form of dedifferentiated carcinoma, seen in 
high-grade renal cell carcinoma. Here, a patient presents with a less common variant in which the 
metastasis appears to have initiated as a dermatological finding. 
Case Presentation 
A 46 year old female with no past medical history presents to the ED with recurrent episodes of dizziness, 
dyspnea, xerostomia, dry lips, generalized weakness, and productive non-bloody cough.  Five months 
prior to admission she noticed a small painless mass on her right shoulder, which she attributed to 
consequence of her rigorous weight training. One month later, she noticed that the mass increased in size.  
She was had insomnia, loss of interest, low energy, loss of concentration, loss of appetite, and irritability. 
Three months after the initial mass, she noticed three more masses. First one on her left posterior hip, 
second on the sole of her right foot, and last one in her right axillary area.  Her vital signs: temperature: 
98.4⁰F, RR 18/min, HR 90/min, and BP 110/70mmHg. Laboratory studies showed hemoglobin 7.9 g/dL, 
hematocrit 25.8%, platelets 568x10
3
 per µL, MCV 63.1fL, BUN 29mg/dL, Creatinine 1.7 mg/dL, calcium 
17.9 mg/dL, and Alkaline Phosphatase 367 U/L. Physical exam revealed a left upper arm mass, a right 
supraclavicular mass, bilateral breast masses, a left hip swelling and tenderness and right sole of the foot 
soft tissue mass (Figure 1& 2).  Chest x-rays showed suspicion of metastatic lesions in the lungs. Patient 
was admitted to the ICU for hypercalcemia. Bone density scan was performed which was negative for any 
osteolytic lesions however, CT scan of abdomen pelvis showed mass in the upper pole of the left kidney 
(Figure 3) as well as a breast ultrasound verifying a 2.9 cm mass in the right breast axillary area.  
Incisional biopsy was performed which showed sarcomatoid renal clear cell carcinoma with metastasis 
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Discussion 
Sarcomatoid renal cell carcinoma is an uncommon, but not rare, neoplasm consisting of typical 
renal cell carcinoma associated intimately with sarcomatoid component. It is important to note 
that sarcomatoid renal cell carcinoma is no longer considered a separate tumor type because it 
can occur with all histologic subtypes. Additionally, according to the World Health Organization, 
of all the renal cell carcinoma’s, the clear cell histologic subtype is by far the most common, 
comprising 70% of all cases [3] 
Although accounting for only 5% of RCCs, the aggressive nature and advanced stage of 
presentation makes sarcomatoid RCC fairly common to practitioners who manage patients with 
metastatic disease. Researchers later termed sarcomatoid characteristics the “final common 
dedifferentiation pathway” for renal tumors [4]. 
The clinical presentation of kidney cancer varies widely and is dependent on the stage at 
diagnosis. In most published series, sarcomatoid tumors are usually extremely large, with a mean 
size of 9 –10 cm, and 90% are symptomatic at presentation. The incidence of metastatic disease 
is extremely high at presentation, with 45%– 84% having evidence of systemic disease. 
Metastases occur at similar locations as with other renal tumors, with the most common sites of 
distant disease being the lungs, bone, nodes, liver, and brain, respectively. One series did report a 
high incidence of bone metastases, but a recent series showed a similar 29% rate of bone 
involvement for sarcomatoid RCCs and nonsarcomatoid RCC. A significant laboratory 
abnormality was microscopic hematuria [4], to which our patient was absent of at the time of 
admission.  
The classical signs of RCC, including hematuria, flank pain, and a palpable abdominal mass, 
are detected in only 10% of RCC cases. Consequently, most cases are diagnosed during 
examination for other causes or by the appearance of metastatic lesions. The breast is an unusual 
site for metastasis from renal cell carcinoma. The reported cases have been of the classic clear 
cell type. However, sarcomatoid renal cell carcinoma can occur and in theory could present as a 
metastatic. Cutaneous metastasis in RCC is rare; accounting for between 1 and 3% of all 
metastases incidence. The most usual location of skin metastases in these patients is the scalp, 
face, and trunk and they are usually single lesions that grow rapidly, are bluish-red in color and 
sometimes pulsating, differential diagnosis performed macroscopically is necessary. Surprisingly, 
all reported cutaneous metastasis cases associated with RCC have occurred high in males [1, 5]. 
In certain cases diagnosis of this condition is made at a late stage of the disease when the cancer 
is widespread and has metastasized in different areas of the body. In most of the cases published 
regarding patients with RCC, the development of skin metastases takes place within six months 
to five years of the initial diagnosis and after performing the nephrectomy, except in some cases 
in which RCC has been diagnosed after removing the skin lesion. We should highlight the 
importance of a precise histological diagnosis to permit the correct identification of the skin 
lesion in order to complete an extension study, since in up to 75% of cases; concomitant organic 
metastases develop [1].  
The pathological studies indicated that our patient’s tumor cells are immunoreactive to 
vimentin, CD10, PAX8 and beta-catenin, focal positive to EMA, MUC-1, FLI-1,  CD99, SMA 
and Factor VIII; they were negative to RCC, PAX2, CK7, s100, MYOD-1, myogenin, CD57, 
CD34, CD31, CD117, ER, Inhibin, HMB-45 and Melan-A.  
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The common sites for skin metastases were the trunk (40%), followed by the scalp (25%) and 
face (8%); of whom 24% had skin metastases at the time of diagnosis. A large Indian study, 
reviewing a total of 306 patients with RCC seen over a 12-year period found only 10 cases (3.3%) 
with skin metastasis, of whom, half of the patients presented with skin metastasis during follow- 
up after nephrectomy. In only one case the skin nodule was actually the presenting symptom [6]. 
Our patient had skin metastases as presenting complaint. Other authors have reported single 
cases. Skin metastasis is considered as a poor prognostic factor for survival. Metastasis at the 
time of diagnosis frequently occurs in RCC, with the skin not infrequently involved. Clinicians 
should be aware of the possibility of primary malignancy in patients presenting with cutaneous 
lesions, therefore a careful examination of the skin is required in patients with RCC. Prompt 
diagnosis and treatment may affect outcome [2].  
Tumor-related growth factors, such as parathyroid-related protein and truncated fibronectin 
growth-promoting substance, may also play an important role in the localization of cutaneous 
metastasis in this region. RCC-related cutaneous metastasis often presents as a solitary, shiny 
skin lesion that is red-to-purple in color. In some cases, however, the lesions are scattered, 
plaque-like, or nodular. The rich vascular component of cutaneous metastasis in RCC may cause 
clinical confusion with hemangiomas, pyogenic granulomas, and Kaposi’s sarcoma. The 
morphological appearance of the lesion’s surface can also imitate cutaneous cysts, cutaneous 
horns, lymphomas, or abscesses. RCC has been diagnosed through cutaneous metastasis when 
the primary tumor was too small to be detected or had an involution. [5] 
The differential diagnosis of metastatic skin lesions may raise important clinical and 
histopathological issues. The detection of the disease’s primary focus and histopathological 
analysis are important when making decisions about treatment. Cutaneous metastasis in RCC is 
often characterized by intradermal nodules with a thin dermal tissue space between the epidermis 
and the tumor tissue [5, 6, and 7].  
The sarcomatoid variant of renal cell carcinoma is very aggressive; many clinical trials are 
using chemotherapy drugs as a treatment. Some of these include a treatment trial at Dana Farber 
Cancer Institute and Beth Israel Deaconess Medical Center where sunitinib in combination with 
gemcitabine are being used in patients with either sarcomatoid histology or poor-risk features. 
Another clinical trial at MD Anderson Cancer Center involving bevacizumab, capecitabine, and 
gemcitabine is under investigation. However, understanding sRCC will lead to better and more 
specific therapies [3]. 
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